We were disappointed to hear that on August 1, 2019 BioMarin announced plans to discontinue preclinical studies in the BMN 290 programme for Friedreich’s Ataxia. BMN 290 is a selective chromatin modulation therapy that has been under investigation as an active preclinical programme since 2017. Read the full press release from BioMarin here.

Posted 02/08/2019